Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes

Area of Science:

• Immunology
• Virology
• Hematology

Background:

• Severe COVID-19 can trigger Cytokine Storm Syndrome (CSS), characterized by profound inflammation and multi-organ dysfunction.
• Understanding COVID-19 CSS requires comparison with established hematological CSS entities.

Purpose of the Study:

• To compare the clinical features, diagnosis, and pathogenesis of COVID-19 CSS with secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy-associated Cytokine Release Syndrome (CRS).
• To review current and emerging therapeutic strategies, including cytokine blockade and signaling pathway inhibition, for various CSS.
• To establish a foundation for future diagnostic criteria for COVID-19 CSS by comparing inflammatory markers and cytokine levels across entities.

Main Methods:

• Literature review and comparative analysis of clinical data, pathogenesis, and therapeutic approaches for four distinct CSS entities.
• Examination of established and emerging markers of inflammation and cytokine profiles.

Main Results:

• COVID-19 CSS shares features with other hematological CSS but has unique characteristics.
• Cytokine-targeting therapies are central to managing CSS, with ongoing trials for COVID-19 CSS.
• Comparative analysis of inflammatory markers and cytokines is crucial for differentiating CSS types.

Conclusions:

• Effective management of COVID-19 CSS involves understanding its similarities and differences with other CSS.
• Targeted immunomodulatory therapies show promise for severe COVID-19 and other CSS.
• Further research is needed to refine diagnostic criteria and optimize treatment for COVID-19 CSS.